(Q33421241)

26 July 2017

title

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies (English)

1 reference

26 July 2017

1 reference

ChEBI release 2020-05-28

David C Smith

1

0 references

author name string

Thea Kalebic

2

1 reference

26 July 2017

Jeffrey R Infante

3

1 reference

26 July 2017

Lillian L Siu

4

1 reference

26 July 2017

Daniel Sullivan

5

1 reference

26 July 2017

Gordana Vlahovic

6

1 reference

26 July 2017

John S Kauh

7

1 reference

26 July 2017

Feng Gao

8

1 reference

26 July 2017

Allison J Berger

9

1 reference

26 July 2017

Stephen Tirrell

10

1 reference

26 July 2017

Neeraj Gupta

11

1 reference

26 July 2017

Alessandra Di Bacco

12

1 reference

26 July 2017

Deborah Berg

13

1 reference

26 July 2017

Guohui Liu

14

1 reference

26 July 2017

Jianchang Lin

15

1 reference

26 July 2017

Ai-Min Hui

16

1 reference

26 July 2017

John A Thompson

17

1 reference

26 July 2017

publication date

18 March 2015

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

33

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

652-663

1 reference

Creative Commons Attribution 4.0 International

26 July 2017

copyright license

start time

18 March 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Proteasome inhibitors in multiple myeloma: 10 years later

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Pharmacodynamic biomarkers in model-based drug development in oncology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Proteasome inhibitors in cancer therapy: lessons from the first decade

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Preclinical data with bortezomib in lung cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Early work on the ubiquitin proteasome system, an interview with Avram Hershko. Interview by CDD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Narrative review: protein degradation and human diseases: the ubiquitin connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0230-X

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435632

Proteasome inhibitors in the treatment of multiple myeloma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25777468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Proteasome inhibition measurements: clinical application

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25777468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-015-0230-X

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference